Loading...

SLS SELLAS LIFE SCIENCES GROUP INC US FDA Inspections 8-K Filing

SLLS

SLS

SELLAS LIFE SCIENCES GROUP INC

(SLS)

2025 8-K

Show Summary

Summary

Financial Statements

Financial Statements

Financial Results

Executive Changes

Interim Analysis

Financial Results

Sublease Extension

Financial Results

Securities Purchase Agreement

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

Collaboration Agreement

Securities Purchase Agreeme...

Compliance Regained with Mi...

Termination of Executives a...

Compliance Regained with Na...

Securities Purchase Agreements

Termination of Sales Agreement

Dispute over Milestone Paym...

Lease Extension

Financial Results Announcement

Securities Purchase Agreeme...

Phase 2a data announcement

Update on Clinical Trial

Financial Results Announcement

Annual Meeting of Stockholders

Virtual Panel Discussion on...

Financial Results Announcement

Financial Results Announcement

Regulation FD Disclosure

Offering and Warrant Amendm...

Underwriting Agreement for ...

Financial Condition

Appointment of CFO

External Links:

SELLAS Life Sciences announced the interim analysis results of its Phase 3 REGAL trial for galinpepimut-S in treating acute myeloid leukemia, highlighting the ongoing development and future milestones while acknowledging risks and uncertainties.

AI Assistant

SELLAS LIFE SCIENCES GROUP INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.